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Background: The pro-inflammatory status of the elderly triggers most of the age-related diseases such as cancer
and atherosclerosis. Atherosclerosis, the leading cause world wide of morbidity and death, is an inflammatory dis-
ease influenced by life-style and genetic host factors. Stimuli such as oxLDL or microbial ligands have been pro-
posed to trigger inflammation leading to atherosclerosis. It has recently been shown that oxLDL activates immune
cells via the Toll-like receptor (TLR) 4/6 complex. Several common single nucleotide polymorphisms (SNPs) of the
TLR system have been associated with atherosclerosis. To investigate the role of TLR-6 we analyzed the association
of the TLR-6 SNP Pro249Ser with atherogenesis.
Results: Genotyping of two independent groups with CAD, as well as of healthy controls revealed a significant
association of the homozygous genotype with a reduced risk for atherosclerosis (odds ratio: 0.69, 95% CI 0.51-0.95,
P = 0.02). In addition, we found a trend towards an association with the risk of restenosis after transluminal coronary
angioplasty (odds ratio: 0.53, 95% CI 0.24-1.16, P = 0.12). In addition, first evidence is presented that the frequency of
this protective genotype increases in a healthy population with age. Taken together, our results define a role for
TLR-6 and its genetic variations in modulating the inflammatory response leading to atherosclerosis.
Conclusions: These results may lead to a better risk stratification, and potentially to an improved prophylactic
treatment of high-risk populations. Furthermore, the protective effect of this polymorphism may lead to an increase
of this genotype in the healthy elderly and may therefore be a novel genetic marker for the well-being during
aging.
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The immune status of the elderly is characterized by 2-
4-fold increased baseline levels of inflammatory media-
tors such as cytokines and acute phase proteins [1]. This
chronic low-level inflammation (recently also termed
inflamm-aging) has been suspected to drive age related
diseases such as atherosclerosis, cancer, diabetes and
Alzheimer’s disease, all of them characterized by chronic
inflammation [2-4].* Correspondence: lutz.hamann@charite.de
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reproduction in any medium, provided the orCoronary artery disease (CAD) is the leading cause of
morbidity and mortality worldwide [5]. It is an inflam-
matory disease with inflammatory markers being ele-
vated, and causally involved in the pathogenesis of CAD
[6]. CAD results in dangerous plaques leading to
stenosis of coronary arteries, which are removed by a
medical procedure termed percutaneous transluminal
coronary angioplasty (PTCA). Restenosis, which is the
main drawback of this treatment, has also been associ-
ated with increased local inflammation. The inflamma-
tory response induced by PTCA correlates with the risk
of restenosis, and anti-inflammatory treatments de-
crease the risk of restenosis [7-10].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have recently been shown to play an important role in
the development of CAD. Several genetic risk loci have
been identified by genome-wide association studies [11].
In line with these results, the release of inflammatory
markers such as IL-6 during CAD, or following PTCA
differs largely between individual patients and this most
likely due to a different genetic background. Single nu-
cleotide polymorphisms (SNPs) have been shown to in-
fluence serum levels of IL-6 and other inflammatory
markers as reviewed by Dahmer et al. [12]. Although
several genome-wide association studies have been per-
formed, the loci identified could only explain some of
the heritability of CAD and other common complex dis-
eases. Therefore, further analysis of SNPs in candidate
genes may improve our understanding of complex dis-
eases such as atherosclerosis [13].
Postulated mediators of atherogenesis, e.g. bacteria such
as Chlamydia pneumoniae or oxLDL, activate the innate
immune system via the TLR-pathway [14]. TLR-associated
SNPs have been found to be potentially involved in altered
susceptibility and course of several diseases [15]. I.e.TLR-4
has been shown to be involved in early atherosclerosis by
comparing knock out mice to control animals: Mice lack-
ing TLR-4 were protected in an atherosclerosis model,
which seemed to be independent from cholesterol levels
[16]. In line with these findings, genetic variations within
the TLR-4 gene in patients have been associated with risk
for atherosclerosis, although conflicting results have been
published (reviewed by den Dekker et al. [17]). Also defi-
ciency of TLR-2 has been associated with lowered diet-
and pathogen induced atherosclerosis in mouse models
[18,19]. Involvement of the activation of the innate im-
mune system via the TLR-pathway in pathogenesis of ath-
erosclerosis as well as TLRs as possible therapeutic targets
for atherosclerosis has been recently reviewed [20-22].
TLR-6 has been shown to mediate inflammatory re-
sponses upon stimulation with oxidized low-density lipo-
protein (oxLDL) in cooperation with TLR-4 [23]. In line,
TLR-4- and TLR-6-knock out mice both have been shown
to express decreased quantities of tissue factor induced by
hypercholesterolemic diet as compared to control mice
[24]. Furthermore, the TLR-6 SNP Pro249Ser has recently
been associated with lower left ventricular wall thickness
and inflammatory response in hypertensive women [25].
In addition, the mutated TLR-6 Ser allele has been shown
to lead to a diminished IL-6 release upon stimulation with
a TLR-6 agonist [26]. Regarding restenosis, TLR-2 the het-
erodimerization partner of both, TLR-1 and TLR-6 in rec-
ognizing bacterial lipoproteins, has been shown to play an
important role in restenosis after revascularization proce-
dures: We could show that a TLR2 SNP is associated with
the inflammatory response and with the risk of restenosis
after PTCA [27].Here we investigated the association of the TLR-6 SNP
Pro249Ser (rs5743810) with susceptibility to atherogen-
esis in two independent patient groups with proven cor-
onary artery disease by comparison with age-matched
healthy control groups. One group that underwent PTCA
and subsequent control angiography after 6 months was
further analyzed for an association of the TLR-6 SNP with
restenosis. We found the homozygous mutated TLR-6
genotype to be significantly associated with a reduced sus-
ceptibility to atherosclerosis (odds ratio of 0.69, 95% CI
0.51-0.95; P = 0.02). However, association with restenosis
after successful PTCA was found to be only of borderline
significance (odds ratio: 0.53, 95% CI 0.24-1.16, P = 0.12),
which is most likely due to the lower sample number.
Comparison of both aged healthy control groups with a
young healthy control group showed a significant increase
(odds ratio 1.53, 95% CI 1.16-2.02, P = 0.003) of the homo-
zygous mutated genotype with age.
Results
TLR-6 SNP Pro249Ser is associated with the risk for
atherosclerosis
207 Caucasian patients with symptomatic CAD as well as
a confirmatory study group of 306 patients that underwent
cardiac surgery were genotyped for the presence of the
TLR-6 SNP Pro249Ser. Two groups of 300, and 305, re-
spectively healthy Caucasian volunteers served as controls.
Compared to healthy controls, the Ser allele was found to
be significantly less frequent in patients (P = 0.008 and
P = 0.23, respectively, Table 1). Combination of both co-
horts resulted in a P-value of 0.007. Genotype distribution
was also significantly different among patients and con-
trols: Employing a recessive model we compared homozy-
gous mutant genotypes with wild-type plus heterozygous
genotypes: In both groups a trend for a decreased fre-
quency of the homozygous genotype could be observed in
patients indicating a protective function of this genotype
(Table 1). Combination of both groups revealed a de-
creased risk for the homozygous Ser/Ser genotype with an
odds ratio of 0.69, 95% CI 0.513-0.953 with a P-value of
0.02 (Table 1).
Presence of the Pro249Ser TLR-6 SNP is associated with a
trend towards the risk for restenosis
The risk of restenosis after successful PTCA has been
associated with an inflammatory response induced by
PTCA. Therefore, we stratified our study group for the
occurrence of restenosis as determined by a control angi-
ography 6 month after successful PTCA. In line with the
previous finding, the TLR-6 Ser allele was also underrep-
resented in the restenosis group. However, these differ-
ences were of borderline significance only (P = 0.05), most
likely due to the low sample number. A trend for a pro-
tective role of the homozygous Ser/Ser genotype regarding
Table 1 TLR-6 genotype distribution in CAD patients and controls
N Variant allele (%) P-value
Genotype (%) Odds ratio (95% CI)
Pro/pro Pro/ser Ser/ser
P-value
ser C/C C/T T/T
Study group
Controls 1 300 278 (46.3)
0.008
87 (29.0) 148 (49.3) 65 (21.7) 0.64




Controls 2 305 268 (43.9)
0.23
97 (31.8) 148 (48.5) 60 (19.7) 0.76




Controls 605 546 (45.1)
0.007
184 (30.4) 296 (48.9) 125 (20.7) 0.69
Patients 513 405 (39.5) 187 (36.5) 247 (48.1) 79 (15.4)
0.513-0.953
0.02
P-values were determined by chi2 test. The odds ratios were determined by comparing the homozygous genotype with the wild type and the
heterozygous genotype.
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0.12 was observed (Table 2).
Frequency of the Pro249Ser TLR-6 SNP increases with age
in healthy controls
Given that coronary artery disease is the major cause of
death in the Western world, we speculated that this
protective Ser249Ser TLR-6 genotype would be overrep-
resented in an elderly cohort of healthy controls in com-
parison to a young healthy control group, where due to
age CAD doesn’t play a role. To test this hypothesis, we
compared 805 young healthy controls (age <50) with
both combined aged healthy control groups of higher
age described above. Indeed we observed a significant in-
crease of the “protective Ser allele” in the high age control
group (P = 0.00006). In line, the homozygous mutated
Ser/Ser genotype also was found more frequently in
higher age (Odds ratio 1.53, 95% CI 1.16-2.02, P = 0.003,
Table 3) indicating this genotype to be a marker for






No restenosis 106 90 (42.5)
0.05
Restenosis 101 67 (33.2)
P-values were determined by chi2 test. The odds ratios were determined by compa
heterozygous genotype.test no significant association could be observed for pa-
tients, old controls and young controls, respectively (P =
0.33, P = 0.94, P = 0.72).
Possible influence of Pro249Ser on TLR-6 protein
structure
To investigate the consequence of the Pro249Ser SNP on
TLR-6 protein structure we performed some “in silico
analysis”. Figure 1 shows three-dimensional structure of
Leucine rich region (LRR) for TLR-6 housing the SNP.
Comparison of CASTp results for wild type and mutant of
TLR-6 LRR region divulged presence of 102 and 93 func-
tional pockets, respectively (Additional file 1: Figure S1).
The mutation resulted in a decrease number of pockets.
The wild type and mutant showed variation in surface
topography of major clefts and cavities (Additional file 2:
Figure S2). As seen from Additional file 3: Table S1 and
Additional file 2: Figure S2, significant decrease in volume
of two major clefts in the mutant was observed. Flexibility
analysis revealed that the wild type was 36.6% rigid whileh or without restenosis
Genotype (%) Odds ratio (95% CI)
Pro/pro Pro/ser Ser/ser P-value
C/C C/T T/T
36 (34.0) 50 (47.2) 20 (18.9) 0.53
45 (44.6) 45 (44.6) 11 (10.9)
0.24-1.16
0.12
ring the homozygous genotype with the wild type and the
Table 3 TLR-6 genotype distribution among young and old healthy controls
N Variant allele (%) P-value
Genotype (%) Odds ratio (95% CI)
Pro/pro Pro/ser Ser/ser
P-value
P value P value P
Study group
Young contr. 805 606 (37.6)
0.00006
316 (39.3) 372 (46.2) 117 (14.5)
1.53
1.16-2.02
0.003Old contr. 605 546 (45.1) 184 (30.4) 296 (48.9) 125 (20.7)
P-values were determined by chi2 test. The odds ratios were determined by comparing the homozygous genotype with the wild type and the
heterozygous genotype.
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value (difference in free energy of the mutation) of −1.50
Kcal/mol owing to change of P249 to S249.
Discussion
Inflammation plays a pivotal role in atherosclerosis and
mediates the effects of many known risk factors of the
disease by altering the behaviour of endothelial as wellFigure 1 3D structure of Leucine rich region (LRR) of TLR-6 housing t
in TLR6 protein (796aa). Numbers indicate amino acid residues for a particu
any region.as smooth muscle cells [28]. In addition, the risk for
restenosis after successful angioplasty is strongly influ-
enced by the inflammatory response to the PTCA pro-
cedure, mediated at least partially by the TLR system
triggering the inflammatory response [7,9].
Here, we add another line of evidence for the involve-
ment of the TLR system in this inflammatory process lead-
ing to atherogenesis. TLR-6 has been shown to mediatehe SNP P249S. Horizontal bar shows distribution of different regions
lar region. Blocks in white are amino acid residues not associated with
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atherosclerosis [23]. Bacterial lipopeptides, also known to
induce atherogenesis, are also recognized by TLR-6 in
combination with TLR-2 and TLR-1 [14]. Our results
shown here indicate an association of the TLR-6 Pro249Ser
SNP with the risk for atherosclerosis, and potentially with
the risk for restenosis after successful PTCA. The reason
for the association with restenosis being only of borderline
significance most likely lies in the limited sample number
since restenosis data were not available for the confirma-
tory study group. However, the differences in percentage
were similar or even more pronounced as found by the
comparing patients and controls regarding atherosclerosis
susceptibility. Limitations of our study are on one hand the
low sample number, and on the other the fact, that little
information about other relevant risk factors potentially
influencing our results was available. Therefore, larger
and well planned prospective studies are needed to con-
firm our results.
In line with our results several mouse models have
currently shown an involvement of TLR-2, which acts as
heterodimer with TLR-1 or −6, in atherogenic processes
[18,19]. It has been suggested that endogenous TLR-2
agonists may have an impact on atherosclerotic disease
progression by the fact that TLR-2 knock out mice exhibit
a decreased severity of experimentally induced athero-
sclerosis [19]. Two studies have shown pro-atherogenic ef-
fects of apoCIII being mediated by TLR-2: In contrast to
wild type mice apoCIII failed to activate monocytes origin-
ating from TLR-2 deficient mice regarding adhesiveness
to HUVECs [29]. Furthermore, apoCIII was not able to in-
duce MCP-1 and IL-6 in adipose tissue from TLR-2 knock
out mice [30].
Elevated IL-6 levels play an important role in athero-
genesis due to detrimental effects on the vascular wall
and endothelial function [31,32]. Supporting our hypoth-
esis of TLR-6 Pro249Ser being athero-protective func-
tional analysis of this SNP has revealed that the Ser/Ser
genotype was associated with a decreased IL-6 release by
stimulated monocytes as well as a lessened NF-κB acti-
vation in transfected HEK 293 cells [26]. In contrast to
IL-6, the release of the athero-protective cytokine IL-10
seems not to be influenced by TLR-6 Pro249Ser [33,34].
It has furthermore been shown that murine aortae ex-
press TLR-6 and that it is crucial for the induction of
vascular dysfunction by Gram-positive bacteria [35]. The
role of TLR-6 deficiency in atherogenesis has recently
investigated employing knock out mice. Endogenous
atherosclerotic stimuli brought about by high fat diet, for
example oxLDL, do not depend on TLR-6 expression,
whereas exogenous stimuli like MALP2, known to be a
TLR-6 ligand, depend on TLR-6 expression [36]. However,
whether the TLR-6 Pro249Ser SNP alters the inflammatory
response in human vascular cells and which stimuli areinvolved currently still remains to be investigated. The
therapeutic potential of TLR modification by TLR agonists
as well as TLR antagonists in cardiovascular dysfunction
has been reviewed recently. Especially compounds modify-
ing TLR-2 and TLR-4 function are considered to be benefi-
cial. Antagonists are thought to lower the inflammatory
burden whereas low concentrations of agonist are thought
to be protective in terms of preconditioning [37]. Our
data indicate that also TLR-6 could be a target of thera-
peutical intervention.
The consequence of the mutation on the protein
structure is evident from our findings. In wild type, the
pocket housing SNP P249S showed differences having
residues interrupted by cavities in proximity of proline
while mutant had pocket residues close to each other in-
dicating potential conformational changes. This con-
formational change is likely to affect binding of ligands
and receptors. Again, substantial decrease in volume of
the clefts is bound to impact capability of mutant pro-
tein to enter into meaningful interactions since majority
of binding regions and active sites are known to be lo-
cated in largest cleft [38]. These aforementioned facts
are further supported by the outcome of flexibility stud-
ies. The wild type protein being more flexible had more
room for ligand induced movements while in mutant lig-
and induced movement will be restricted to side-chain
rearrangements only [39]. So, the mutation makes the
structure difficult to undergo functionally relevant con-
formations making it harder for inducing possible drug
molecules. The significantly low DDG value pointed out
considerable decrease in stability in the mutant. All
these confirmed that the TLR-6 protein structure and
functionality are influenced by mutation.
Healthy aging depends most likely on the delay of onset
of age related diseases such as coronary artery disease,
Alzheimer’s disease, type 2 diabetes and cancer [40]. Gen-
etic variations associated with age-related diseases there-
fore have been suspected to be involved in successful
aging [41]. A large number of genes, and thereby a large
number of SNPs, are involved in pathogenesis of these
common diseases. Therefore, a genetic signature for lon-
gevity has been suggested by Sebastiani et al. [42]. They
established networks for coronary artery disease and
Alzheimer’s disease including 130 disease-associated genes
building a genetic risk model [42]. However, since TLR-6
SNPs have not been associated with either of these dis-
eases so far, TLR-6 was not included into this model. Of
note, since chronic inflammation is central for age-related
diseases these longevity networks are both centred on
NFκB activation [42], which is the main signalling pathway
following TLR stimulation. Having shown that the TLR-6
ser/ser genotype protects from atherosclerosis we could
show here that this genotype is increased in the healthy eld-
erly. One could speculate that this less functional TLR-6
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inflamm-ageing during older age.
Conclusion
Our results suggest that the less functional TLR-6 Ser/
Ser genotype protects from atherosclerosis as well as
from restenosis after successful PTCA. The underlying
mechanism remains to be investigated but it is tempting
to speculate that a lessened inflammatory response
brought about by a dysfunctional TLR-6 is responsible
for this protective effect. Genotyping of patients at risk
for CAD may improve the risk stratification and lead to
a better prevention regime for both, atherosclerosis and
restenosis. Furthermore, this SNP may be a novel gen-




The first study group has been described in detail previ-
ously as study group “A” [27]. In brief, the group consisted
of 207 Caucasian patients with symptomatic coronary ar-
tery disease who underwent PTCA. Significant stenosis
was confirmed by quantitative coronary angiography. All
patients were hospitalized, clinically stable, and were rou-
tinely checked after 6 month for follow-up angiography.
Confirmatory group
The confirmatory group has been described previously
[43]. 306 patients undergoing elective cardiac surgery
(coronary artery bypass graft with/or without valve sur-
gery) have been enrolled by a single-center study.
Controls
DNA from 300 healthy controls obtained from the Pop-
Gen biobank (University of Kiel, Germany) was included
as control for the study group (Control group 1). DNA
from 305 healthy controls from the PopGen biobank was
included as control for the confirmatory group (ControlTable 4 Patient characteristics
Study group Confirmatory grou
Mean age, SD 59.8, 9.94 68.2, 9.0
Male/female (%) 77/23 75/25
Diabetes (%) 9.8 45.0
Smoker (%) 25.0 nd
Hypertension (%) 41.4 nd
BMI 27.3 27.8
Procedure nd ACVB 82%
ACVB + VS 18%
ACVB: aorto coronary vein bypass, VS: valve replacement, nd: not determined.group 2). A third control group of 805 young healthy
volunteers was analyzed to compare genotype distribu-
tion dependent on age (Control group 3). Participants
reported to not have had a chronic disease or regularly
use medication at recruitment.
Characteristics for all patients and controls are summa-
rized in Table 4. All participants were of Caucasian origin.
All studies were approved by the local ethics committees,
and all investigations were carried out in accordance with
the ethical guidelines of the 1975 Declaration of Helsinki.Genotyping
Genomic DNA was prepared by standard procedures from
whole blood. Genotyping for TLR-6 SNP Pro249Ser
(rs5743810) was performed by melting curve analysis.
Melting curve analysis was carried out employing primers
gaaagactctgaccaggcat (forward), ctagtttattcgct atccaagtg
(reverse), and FRET-hybridisation probes: accagaggtc-
caaccttactgaa-FL and LC-red 640-ttaccctcaaccacatagaaac-
gacttgga resulting in melting points of 61°C and 52°C for
the wild-type,, and the mutated allele, respectively. Geno-
typing was executed using standard PCR conditions apply-
ing the LightCycler LC 480 platform (Roche Diagnostics,
Mannheim, Germany). Primers and probes were designed
by O. Landt (TIB-MOLBIOL, Berlin, Germany). Genotyp-
ing by melting curve analysis was validated by reanalyzing
10% of the samples using a conventional restriction frag-
ment polymorphism analysis. Digestion of the 194 bp
PCR product with AvaII results in two fragments of 67 bp
and 127 bp in wild type individuals, whereas the TLR-6
SNP Pro249Ser destroys this restriction site. Restriction
digests were analyzed on a 3% agarose gel. No divergent
results were observed.Hardy weinberg equilibrium
All control groups were analyzed for Hardy Weinberg
equilibrium (HDW). Deviations from HDW could not
be detected (control group 1: P = 0.89, control group 2:
P = 0.79, control group 3: P = 0.44).p Controls 1 Controls 2 Controls 3
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The structure of Leucine rich region (LRR) of TLR-6 was
determined by homology modelling technique using MOD-
ELLER 9.11 program [44]. Owing to lack of homology and
availability of suitable templates, structure of other regions
could not be determined. Swiss-Pdb Viewer [45] was used
to perform energy minimizations. Structures were visua-
lised with PyMol (www.pymol.org). Algorithms ProSA [46],
PROCHECK [47], PROVE and ERRAT (http://nihserver.
mbi.ucla.edu/SAVS/) were used for structure evaluations.
Surface topography and pockets were determined with
CASTp [48]. These pockets contributed towards function-
ing and understanding properties [48]. Clefts and cavities
were predicted using ProFunc [49]. These regions house
possible functional biologically important residues. The area
and volume of clefts are significant for interacting resi-
dues, ligand binding, receptor binding etc. [38]. Flexibil-
ity studies were based on the software StoneHinge [50].
The implication of mutation on structure was studied
using I-Mutant 3.0 [51]
Statistics
P-values for genotype associations were determined by
chi2 test. Risk factors were estimated by logistic regres-
sion analysis adjusting for age and sex using SPSS Statis-
tics 19 software.
Additional files
Additional file 1: Figure S1. Pockets for A) wild type and B) mutant of
human TLR6 LRR region. Pocket housing the SNP is marked red.
Additional file 2: Figure S2. Major clefts and cavities for wild type and
mutant of human TLR6 LRR region.
Additional file 3: Table S1. Comparison of volume of 4 major clefts for
wild type and mutant protein.
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